Clinical Trials
8 trialsNCT07165886 2026-04-24
Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2/3 Recruiting
NCT07366801 2026-01-26
Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 2/3 Recruiting
NCT03512756 2024-11-06
A Randomized Phase 2/3 Multi-Center Study of SM-88 in Participants With Metastatic Pancreatic Cancer
Tyme, Inc
Phase 2/3 Terminated
NCT04987463 2024-02-08
ViRap
Children's Memorial Health Institute, Poland
Phase 2/3 Unknown
NCT03826628 2023-09-08
Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated With Tuberous Sclerosis Complex
Dermatology Specialties Limited Partnership
Phase 2/3 Completed
NCT03047980 2021-11-01
Trial of Sirolimus for Cognitive Impairment in Sturge-Weber Syndrome
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Phase 2/3 Completed
NCT00922129 2014-01-14
Effectiveness of Conversion to Sirolimus Versus Calcineurin Inhibitor (CNI) Reduction in Renal Transplant Patients With Prostate Cancer
St. Joseph's Healthcare Hamilton
Phase 2/3 Withdrawn
NCT00328770 2013-06-24
De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma
University of Alberta
Phase 2/3 Completed